Replimune, Inc.

Contributing Author

Recent Articles by Replimune, Inc.

Jul-30	Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma REPL REPL +107.41% GlobeNewswire
Jun-29	Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update REPL GlobeNewswire
Jun-26	Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma REPL GlobeNewswire
May-31	Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting REPL GlobeNewswire
May-30	Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting REPL GlobeNewswire
May-29	Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA REPL +85.68% GlobeNewswire
Apr-27	Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting REPL +10.74% GlobeNewswire
Apr-10	Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma REPL -19.46% REPL -64.29% GlobeNewswire
Mar-02	Replimune to Present at Two Upcoming Investor Conferences REPL -6.41% GlobeNewswire
Feb-03	Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update REPL +5.81% GlobeNewswire
Dec-18	Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference REPL GlobeNewswire
Nov-07	Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025) REPL GlobeNewswire
Nov-06	Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update REPL GlobeNewswire
Oct-20	Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma REPL +98.78% GlobeNewswire
Oct-19	Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025 REPL GlobeNewswire
Sep-18	Replimune Provides Update Following Type A Meeting with FDA REPL -39.40% GlobeNewswire
Sep-02	Replimune Announces Type A Meeting Scheduled with FDA REPL +9.26% GlobeNewswire
Aug-07	Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update REPL GlobeNewswire
Jul-22	Replimune Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma REPL -77.24% GlobeNewswire
Jul-11	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) REPL GlobeNewswire

Replimune, Inc.

Recent Articles by Replimune, Inc.

Upgrade your Finviz experience